THE RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS OF CHLORPROPAMIDE

被引:2
|
作者
KALLIO, J
HUUPPONEN, R
PYYKKO, K
机构
[1] Departments of Pharmacology and Clinical Pharmacology, University of Turku
关键词
Chlorpropamide; Debrisoquine phenotype; Metabolism; Pharmacogenetics; Pharmacokinetics;
D O I
10.1007/BF02657068
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and urinary metabolite pattern of a single oral dose of chlorpropamide 250 mg have been studied in 6 extensive and 5 poor metabolizers of debrisoquine. Ammonium chloride was given orally to acidify the urine in order to make elimination of the parent drug dependent on metabolism alone. The concentration profile in serum and the pharmacokinetic parameters of the parent drug were similar in both groups. However, the ratio in urine of unchanged chlorpropamide to its hydroxylated metabolites was higher in poor than in extensive metabolizers. © 1990 Springer-Verlag.
引用
收藏
页码:93 / 95
页数:3
相关论文
共 50 条
  • [41] HYPOTENSIVE RESPONSE TO DEBRISOQUINE AND HYDROXYLATION PHENOTYPE
    IDLE, JR
    MAHGOUB, A
    LANCASTER, R
    SMITH, RL
    LIFE SCIENCES, 1978, 22 (11) : 979 - 983
  • [42] MEXILETINE PHARMACOKINETICS AND DEBRISOQUINE HYDROXYLATOR STATUS
    LLEDO, P
    ABRAMS, SML
    JOHNSTON, A
    PEARSON, RM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (06) : 2393 - 2393
  • [43] EFFECT OF SUCRALFATE ON THE ABSORPTION AND PHARMACOKINETICS OF CHLORPROPAMIDE
    LETENDRE, PW
    CARLSON, JD
    SEIFERT, RD
    DIETZ, AJ
    DIMMIT, D
    JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (08): : 622 - 625
  • [44] DEBRISOQUINE HYDROXYLATION PHENOTYPE IN SLE PATIENTS
    SEIDEMAN, P
    ALVAN, G
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1989, 18 (01) : 63 - 64
  • [45] CHLORPROPAMIDE HYPOGLYCEMIA - LACK OF CORRELATION WITH PHARMACOKINETICS
    BRASELTON, WE
    HUFF, TA
    BRANSOME, ED
    DIABETES, 1975, 24 : 396 - 396
  • [46] PHARMACOKINETICS AND BIOTRANSFORMATION OF CHLORPROPAMIDE IN RAT AND DOG
    TAYLOR, JA
    DRUG METABOLISM AND DISPOSITION, 1974, 2 (03) : 221 - 227
  • [47] DEBRISOQUINE OXIDATION IN AN AUSTRALIAN POPULATION
    PEART, GF
    BOUTAGY, J
    SHENFIELD, GM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 (05) : 465 - 471
  • [48] ACETYLATION AND OXIDATION PATHWAYS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - INCREASED FREQUENCY OF THE POOR-METABOLIZER DEBRISOQUINE OXIDATION PHENOTYPE
    BAER, AN
    MCALLISTER, CB
    PINCUS, T
    WILKINSON, GR
    WOOSLEY, RL
    CLINICAL RESEARCH, 1985, 33 (02): : A279 - A279
  • [49] HALOPERIDOL DISPOSITION IS DEPENDENT ON DEBRISOQUINE HYDROXYLATION PHENOTYPE
    LLERENA, A
    ALM, C
    DAHL, ML
    EKQVIST, B
    BERTILSSON, L
    THERAPEUTIC DRUG MONITORING, 1992, 14 (02) : 92 - 97
  • [50] MOLECULAR GENOTYPING TO PREDICT DEBRISOQUINE HYDROXYLATION PHENOTYPE
    DALY, AK
    ARMSTRONG, M
    IDLE, JR
    LANCET, 1990, 336 (8719): : 889 - 890